A record of what Sudip Bandyopadhyay said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on domestic-focused pharma companies, which are growing at a 25% CAGR. Recommends companies with limited US exposure, citing Mankind Pharma as a long-term positive pick due to 95% of its business coming from domestic sales.”
Nifty PharmaBullishCalled 06 Oct 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Sudip Bandyopadhyay’s full track record